Saad Usmani, MD, MBA, FACP, reviews the GEM-CESAR trial data presented at ASH 2022 on a potential curative strategy for high-risk smoldering myeloma and discusses his treatment strategy for this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results